The Efficacy and Safety of using Nebulized Antibiotics in Treatment of Ventilator-Associated Pneumonia

Arafa, O.S.; Essawy, T.S.; Aglan, B.M.; Attaya, E.A.

doi:10.21608/bjas.2019.187098

The Efficacy and Safety of using Nebulized Antibiotics in Treatment of Ventilator-Associated Pneumonia

Document Type : Original Research Papers

Authors

¹ Cardiology Dept., Faculty of Medicine, Benha Univ., Benha, Egypt

² Chest Dept, Faculty of Medicine, Benha Univ., Benha, Egypt

³ Cardio thoracic Dept, Faculty of Medicine, Benha Univ., Benha, Egypt

⁴ Critical Care Dept, Faculty of Medicine, Benha Univ, Benha, Egypt

10.21608/bjas.2019.187098

Abstract

Development of ventilator- associated pneumonia [VAP] is associated with high morbidity and mortality rates. VAP mortality ranges between 5.8% and 27% [1]. Routine administration of intravenous antibiotics does not reach a bactericidal concentration in lung tissues. intravenous antibiotics are mainly detected in respiratory segments of lungs, but not in sputum [2].This study was conducted on 60 patients who were admitted to critical care department at Benha University Hospital and diagnosed with Ventilator Associated Pneumonia [VAP]. patients were divided into two groups: Group A included 30 patients have received only systemic antibiotics and Group B included 30 patients have received systemic and nebulized antibiotics. In this study the clearance of organism, resistance, superinfection and combined [resistance and super infection] were significantly different in group A vs.B .There was significant decrease regarding creatinine level in group B vs. A .There were significant reduction in duration of MV and length of ICU stay in group B vs. A.Nebulized Amikacin plus ceftazidime are effective in the treatment of VAP.